AI-Driven Drug Discovery

Reduce redundancy and accelerate disease-specific target discovery.

Harnessing machine learning and computational biology to pinpoint disease targets, prioritize druggable pockets, and validate therapeutic potential early to reduce downstream clinical failure.

• Target tractability and druggability assessment
• Genomic, proteomic, and disease-pathway integration
• Deep docking validation for binding pocket identification
• Impact: 20% cost savings, 6 months saved

Screen ultra-large virtual libraries with machine learning predictive power.

Deploying AI-driven Quantitative Structure-Activity Relationship (QSAR) and virtual screening to rapidly predict compound bioactivity, solubility, and selectivity before chemical synthesis.

• Ultra-large virtual library screening
• Bioactivity prediction modeling and affinity scoring
• Hit expansion and SAR exploration
• Impact: >30% experimental efficiency, 4 months saved

AI synthesis route prediction and de novo molecular design.

Coupling generative AI models with retrosynthetic route planning to design optimized drug candidates with superior ADMET profiles and simplified synthetic feasibility.

• Retrosynthesis route prediction and feasibility scoring
• Multi-parameter optimization (MPO) for drug-likeness
• De novo molecular generation and scaffold hopping
• Impact: 70% fewer compounds synthesized, 9 months saved

Predictive ADMET and translational biomarker integration.

Bridge computational candidate discovery directly with laboratory synthesis and PK/PD evaluation, streamlining preclinical development and minimizing animal usage.

• In-silico ADMET property prediction and PKPD modeling
• Translational biomarker identification for efficacy and safety
• Agile synthetic chemistry support for rapid experimental validation